Unlock Your Body’s Regenerative Potential

Peptide Therapy Online: What Is Approved, What Can Be Compounded, and What to Avoid (October 2026 Update)

Peptides are short chains of amino acids, the building blocks of proteins. A few have passed full FDA review and are sold as prescription drugs. Many others are sold online with big promises and little human research behind them.

Federal rules on peptides changed several times in 2025 and 2026, and much of what is online is out of date. Here is where things stand as of October 24, 2026, so you can tell a legitimate online peptide therapy consult from a site that just sells vials.

FDA-approved peptides vs. compounded peptides vs. “research” peptides

Three very different kinds of products are sold as “peptides”:

• FDA-approved peptide drugs. These have been tested in clinical trials and have an FDA label that says who they are for. Examples include tesamorelin (Egrifta), bremelanotide (Vyleesi), and the GLP-1 medicines used for diabetes and weight management.
• Compounded peptides. A state-licensed compounding pharmacy prepares these for one patient from a prescription. FDA states plainly that compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are sold.
• “Research use only” peptides. These are sold online as “not for human consumption.” They are not approved drugs and are not compounded under a prescription. There is no reliable way to know what is in the vial.

Which substances can a 503A pharmacy legally compound?

Under federal law, a 503A compounding pharmacy may use a bulk drug substance only if it meets one of three tests: it has a USP or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A bulks list (21 U.S.C. 353a(b)(1)(A)(i)). That list, set out in 21 CFR 216.23, still names only six substances, and none of them is a wellness peptide.

While FDA works through nominations, it sorts nominated substances into categories. Under its January 2025 interim policy, only Category 1 substances get enforcement discretion. Substances in Category 2 (significant safety risks), Category 3 (nominated without enough support), or in no category at all do not get that protection (FDA 503A bulk substances page).

Current FDA status of commonly marketed peptides

The table below is based on FDA’s 503A categories list updated May 14, 2026, FDA’s safety-risks page updated April 22, 2026, and current FDA drug labels.

FDA’s Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to discuss adding BPC-157, TB-500, KPV, MOTs-C, emideltide (DSIP), Semax and Epitalon to the bulks list (meeting notice). Committee votes are advice only. Any addition requires FDA rulemaking, and as of October 24, 2026 FDA has not published a rule adding any of these peptides. Another meeting on GHK-Cu, LL-37, dihexa, Melanotan II and PEG-MGF is planned before the end of February 2027 (FDA).

Can you get a BPC-157 prescription online?

As of October 24, 2026, BPC-157 is not an FDA-approved drug. It is not on the 503A bulks list, and it is not in Category 1. That means a 503A pharmacy does not have a clear legal path to compound it for you, even with a prescription. Being removed from Category 2 in April 2026 did not make it compoundable. It happened because the nominators withdrew, and FDA still posts its earlier safety summary.

The human evidence is also thin. A 2025 systematic review found 36 studies, of which 35 were preclinical and only 1 was clinical. A 2026 systematic review found three small human studies with a total of 30 people, all judged poor quality. The authors advised against clinical use outside regulated trials.

If a website offers you BPC-157 today with no questions asked, or sells it as “research use only,” treat that as a red flag. A licensed provider can talk with you about your injury or symptoms and about treatments that are legally available. You can check any online pharmacy with FDA’s BeSafeRx resource.

How a legitimate online peptide therapy consult works

1. Health history. You share your goals, symptoms, medicines, past diagnoses and any history of cancer, heart disease or diabetes.
2. Labs when indicated. Your provider orders blood work only when it is relevant to the treatment being considered.
3. Provider decision. A licensed provider decides whether any treatment is appropriate. They prescribe only what is medically appropriate and legally available, and “no” is a possible answer.
4. Licensed pharmacy. Prescriptions go to a state-licensed pharmacy, never to a “research” supplier.
5. Follow-up. You and your provider review progress, side effects and labs, and decide together whether to continue.

Safety and monitoring

Even approved peptides carry real risks, so any peptide therapy plan needs follow-up. The tesamorelin label warns about raised IGF-1 levels, fluid retention, glucose intolerance and hypersensitivity reactions. It also says any past cancer must be inactive, with treatment complete, before starting. The bremelanotide label warns about a temporary rise in blood pressure after each dose, nausea, and focal darkening of the skin. For unapproved peptides, FDA’s safety summaries note limited or no human safety data and, for some, possible immunogenicity (an immune reaction to the peptide itself). If you also use TRT or HRT for women, your provider should review everything together. For GLP-1 options, see our semaglutide weight loss page.

What online peptide therapy costs at MultiGen

MultiGen Wellness is a self-pay practice. It costs $247 to start, which includes your first provider visit, and then $97 per visit. Medications are priced separately, and you can see current prices on our pharmacy page. We do not bill insurance, and we do not take HSA or FSA cards directly.

Peptide therapy online: frequently asked questions

Are compounded peptides FDA-approved?

No. FDA says compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are sold. Some peptides, like tesamorelin and bremelanotide, also exist as FDA-approved brand-name drugs.

Did FDA make BPC-157 legal in 2026?

No. FDA removed it from Category 2 in April 2026 after the nominations were withdrawn, and an advisory committee discussed it in July. As of October 24, 2026, it is not on the 503A bulks list or in Category 1.

Is TB-500 the same as thymosin beta-4?

TB-500 is marketed as a fragment of thymosin beta-4. FDA reports no human exposure data for it, and it is not on the 503A bulks list.

Can I get CJC-1295 or ipamorelin from a compounding pharmacy?

Neither is on the bulks list or in Category 1, after their 503A nominations were withdrawn. A licensed provider can tell you which options, if any, are appropriate and legally available for you.

Is PT-141 approved for men?

No. The FDA label for Vyleesi (bremelanotide) covers premenopausal women with acquired, generalized hypoactive sexual desire disorder. It states that the drug is not indicated for men.

Are “research use only” peptides safe to inject?

They are not approved for human use, not made under a prescription, and not checked for purity or dose. Use FDA’s BeSafeRx tools to find a state-licensed pharmacy instead.

Do I need labs before peptide therapy?

Sometimes. Your provider decides based on your history and the treatment being considered. Some labels, such as tesamorelin’s, call for checking glucose and IGF-1 during treatment.

Talk to a licensed provider

Have questions about peptides? Contact MultiGen Wellness or call 1-800-259-0015. A licensed provider will review your history and explain what is appropriate and legally available for you.